Adaptive Biotechnologies prices IPO at $20 a share, above previous range of $18 to $19 Jun. 27, 2019 at 8:31 a.m. ET by Sarah Toy Adaptive Biotech prices IPO at $20 a share
Full Answer
When is adaptive Biotechnologies'next quarterly earnings announcement?
Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Adaptive Biotechnologies. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) announced its quarterly earnings data on Tuesday, February, 15th.
Why is WeWork investing in adaptive Biotechnologies?
WeWork Wants In. Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.
How long will your adaptive engineering solution last?
Thirty years of Adaptive engineering assure that your solution will last. Click below to learn more about Loc-N-Load® for LED walls, HoverPro® for LCD video walls and Fly-Ware® projector cages.
Should I buy or sell Adaptive Biotechnologies stock right now?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. Ther...
What is Adaptive Biotechnologies' stock price forecast for 2022?
8 brokerages have issued 1-year price targets for Adaptive Biotechnologies' stock. Their forecasts range from $7.50 to $50.00. On average, they exp...
How has Adaptive Biotechnologies' stock performed in 2022?
Adaptive Biotechnologies' stock was trading at $28.06 at the beginning of the year. Since then, ADPT shares have decreased by 75.2% and is now trad...
When is Adaptive Biotechnologies' next earnings date?
Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecas...
How were Adaptive Biotechnologies' earnings last quarter?
Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.44) EPS for the q...
What guidance has Adaptive Biotechnologies issued on next quarter's earnings?
Adaptive Biotechnologies issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the perio...
Who are Adaptive Biotechnologies' key executives?
Adaptive Biotechnologies' management team includes the following people: Mr. Chad M. Robins M.B.A , M.B.A., Co-Founder, CEO & Chairman (Age 47,...
What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?
51 employees have rated Adaptive Biotechnologies CEO Chad Robins on Glassdoor.com . Chad Robins has an approval rating of 92% among Adaptive Biote...
Who are some of Adaptive Biotechnologies' key competitors?
Some companies that are related to Adaptive Biotechnologies include Ablynx (ABLYF) , Abcam (ABCM) , Novavax (NVAX) , Vir Biotechnology (VIR) ,...
What is adaptive biotechnology?
Pacific Time / 9:40 a.m. Eastern Time Goldman Sachs 42nd Annual Global Healthcare ConferenceFireside Chat on Tuesday, June 8th at 12:50 p.m. Pacific Time / 3:50 p.m. Eastern Time Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com. About Adaptive BiotechnologiesAdaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations201-396-1687Carrie Mendivil, Gilmartin [email protected] ADAPTIVE MEDIABeth [email protected]
What is adaptive immunoseq?
Adaptive’s immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminishedSEATTLE, June 09, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that immunoSEQ® T-MAP™ COVID was u
How many new apartments will be built in 2021?
According to a recent report from RENTCafé, 20,100 new apartments will be created out of 151 repurposed buildings in 2021, including old offices, hotels, and factories. In 2020, more than 5,800 new apartments sprung up in converted offices, while this year there have been an estimated 7,400 new units -- an all-time high.
What is the Vickers top buyer and seller report?
Daily – Vickers Top Buyers & Sellers for 08/13/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
How much of adaptive biotechnologies stock is owned by insiders?
34.70% of the stock of Adaptive Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.
What is adaptive biotechnology's revenue for 2021?
Adaptive Biotechnologies issued an update on its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $148 million-$155 million, compared to the consensus revenue estimate of $152.70 million.
What is adaptive biotechnology?
It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.
Does adaptive biotechnology pay dividends?
Adaptive Biotechnologies does not currently pay a dividend.
Key Data Points
Primary metrics and data points about Adaptive Biotechnologies Corporation.
Environmental, Social, and Governance Rating
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Where is adaptive technologies group?
By submitting this form, you are consenting to receive marketing emails from: Adaptive Technologies Group, 1635 East Burnett Street, Signal Hill, CA, 90755, http://www.adapttechgroup.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
What is adaptive video wall?
Adaptive provides mechanically engineered custom structural and load-rated video wall frames, direct view towers and projector frames to solve for a wide range of permanent indoor and outdoor applications. Adaptive’s install solutions accommodate all makes and models of LCD and LED monitors and Digital Projectors. Click below to view Video Mounting & Rigging Categories.
